Chemotherapy agents and other chemicals
Platinum drugs were synthesized by Johnson Matthey Technology Centre (Reading, Berkshire, UK) or AnorMED (Langley, BC, Canada). Structures of platinum agents have been published previously (Kelland et al, 1992a (Kelland et al, , 1992b Holford et al, 1998) . Doxorubicin, etoposide and paclitaxel were obtained through the Royal Marsden NHS Trust Hospital Pharmacy. All other chemicals were obtained from Sigma Chemicals (Poole, UK) unless otherwise stated.
Cytotoxicity assays
Sulphorhodamine B (SRB) and microtetrazolium (MTT) growth inhibition assays were performed to assess chemosensitivity as described previously (Kelland et al, 1992a) . Unless otherwise indicated, drug exposure was continuous for 96 h. For clonogenic survival assays, 1000 cells of A2780BCL-2 and A2780 vector (neo) cell lines were allowed to attach overnight in triplicate T25 flasks. Cisplatin exposure was for 2 h. After 7 days, colonies with >50 cells were stained with methylene blue and counted.
Rate of apoptosis
This was determined by measuring cellular detachment from the monolayer following drug exposure as described previously (Ormerod et al, 1996) .
Western blotting
This was performed as described previously using sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) separation and transfer to nitrocellulose membranes and visualization by enhanced chemiluminescence reagents (ECL) (Holford et al, 1998) . Semiquantitative levels were determined by scanning densitometry and analysis by Imagequant software. Densitometric levels were adjusted to a control level from one line for the ovarian cell lines and another line for the xenografts. Antibodies used for detection were BCL-2 (DAKO), , BCL XL (Santa Cruz S-18), BAK (Calbiochem-AB-1), p21 (Santa-Cruz C-19) and p53 (Santa Cruz DO-1). 
Statistical analyses
When appropriate, statistical significance was tested using a twotailed Student's t-test; a P-value of ≤0.05 was considered as significant. All values shown are means with the corresponding standard error of the mean. Correlation analyses were determined by linear regression or by Spearman rank and performed using GraphPad Prism Software.
RESULTS

Characterization of BCL-2 family protein levels in human ovarian cell lines and xenografts
Levels of BCL-2, BAX, BCLxL and BAK in our panel of 12 parental human ovarian cell lines as measured by Western blotting and subsequent densitometry are presented in Figure 1A -D respectively and related to sensitivity to cisplatin. The densitometric levels may be divided into three bands; < 10 equals absent or very low levels; 10-60 represents low to moderate levels; and levels above 60 represent moderate to high levels. Levels of BCL-2 appeared inversely related to cisplatin sensitivity; many of the resistant cell lines such as SKOV-3, 59M, OVCAR-3 possessed relatively low levels while high levels were observed in the cisplatin sensitive lines 41M and CH1. Spearman rank correlation analysis revealed a significant inverse relationship between sensitivity and BCL-2 levels (r = -0.81; P = 0.0022). There was no significant relationship between the level of any of the remaining proteins and the 96-h IC 50 µM to cisplatin in the cell lines (BAX r = -0.32; BCL XL r = 0.47; BAK r = -0.17). BCL-2 protein levels in acquired platinum drug-resistant cell lines showed no consistent pattern (data not shown). For example, in the CH1 (and OVCAR-3) cell lines, platinum-and platinum analogue-resistant cell lines had higher levels of BCL-2 protein (1.1-to 2.2-fold), but in the 41M (and OV1P and PXN94) lines, the platinum-resistant lines had significantly lower levels (0.22-0.49). Interestingly, in the A2780 cell lines BCL-2 was undetectable in the parent and cisR lines, but in the A2780/ZD0473 R line the levels were significantly higher. Kelland et al (1992a, b) and Jones et al (1993) . Levels of the BCL-2 family proteins in a panel of human ovarian carcinoma xenografts of varying responsivenesss to cisplatin are shown in Table 1 . Spearman correlation analysis showed no significant correlation (P > 0.05) between responsiveness to cisplatin (growth delay) and levels of BCL2, BAX, BCL XL or BAK. As with the pairs of in vitro cell lines, there was no consistent pattern in protein levels.
Characterization of an A2780 BCL-2 stable transfected line
The A2780BCL-2 line, in contrast to the vector control, was shown to have enhanced expression of the BCL-2 protein (data not shown), similar doubling times (21.1 ± 0.9 h and 20.1 ± 1.1 h respectively) and similar levels of platinum accumulation and DNA platination following exposure to cisplatin (data not shown). The sensitivity of the A2780 vector (neo) control and BCL-2 transfect to cisplatin was determined by 3 independent assays (MTT, SRB - Figure 2A ; and clonogenic - Figure 2B ) and, for the short-term colourimetric assays at 48-, 72-and 96-h post-drug exposure. Figure 2A reveals an interesting pattern of relative response vs time of assay. Whereas at 48 and 72 h post-drug exposure the BCL-2-transfected line was more resistant to cisplatin than the vector control, at 96 h the reverse was true with the BCL-2 line being significantly more sensitive than the vector control by both assays. Results of a colony forming assay ( Figure 2B ) showed no significant difference in sensitivity between the lines. Results using the 96 h SRB growth inhibition assay for a range of platinum and other standard antitcancer agents of diverse mechanisms of action (e.g. topoisomerase I and II inhibitors, tubulin interactive drugs) showed a tendency in all cases for the A2780BCL-2 transfect to be more sensitive than the vector control although this only reached statistical significance in the cases of cisplatin and the topoisomerase I inhibitor camptothecin (data not shown).
The rate of cellular detachment following exposure to 10 µM cisplatin for 2 h was used an indicator of apoptosis in these cell lines (Ormerod et al, 1996) . Results are shown in Figure 2C . At 48 h post-exposure, there was greater detachment with the vector control line (11.1 ± 2.6% vs 6.0 ± 0.41% in A2780BCL-2). However, by 96 h, the trend was in the opposite direction (38.3 ± 2.7% in vector control vs 47.5 ± 3.8% in A2780BCL-2).
Following exposure to 25 µM cisplatin (5 times the IC 50 ) for 2 h, in the A2780BCL-2 transfect there was induction of BCL-2, BAX and BAK, some induction of p53 and p21 but no marked induction of BCL XL . In contrast, the most notable differences for the vector control were: (1) a decrease in the level of BAK, (2) no induction of BCL-2, and (3) greater induction of p53 and p21. The responses of the BAX and BCL XL proteins were similar in both lines (data not shown).
Characterization of A2780cisR and SKOV-3 bax transfects and CH1 BCL XL transfect
BAX protein levels were 1.4-fold higher in A2780cisR and sixfold higher in SKOV3 transfects when compared to vector controls. The sensitivity of the transfected lines as measured by the 96-h SRB cytotoxicity assay to four DNA-interactive agents (cisplatin, ZD0473, doxorubicin and etoposide) and four tubulin-interactive agents (paclitaxel, docetaxel, vinblastine and colchicine) showed that there were no significant differences in sensitivity within the two cell line pairs to any of the drugs evaluated.
BCL XL levels were fourfold higher in the CH1-transfected line compared with the vector control. The 96-h SRB cytotoxicity assay results showed a significant increase in resistance in the transfected line compared with the control for ZD0473 alone (IC 50 in µM of 0.6 ± 0.08 for CH1puro and 1.53 ± 0.4 for CH1BCL XL ; RF 2.56, P = 0.05), although the parental non-transfected CH1 line showed a similar sensitivity to that of the BCL XL transfect. For all of the remaining drugs there was no significant difference in sensitivity between the two isogenic BCL XL lines (e.g. cisplatin IC 50 in µM of 0.201 ± 0.04 for CH1puro and 0.26 ± 0.02 for CH1BCL XL ; RF 1.3) (remaining data not shown).
DISCUSSION
This study has addressed the possible role of BCL-2 and three other commonly described members, two pro-apoptotic (BAX and BAK) and one other anti-apoptotic (BCL XL ) in determining the cisplatin sensitivity of panels of human ovarian carcinoma cell lines and xenografts. The major findings from this study were: (1) overexpression of BCL-2 protein in human ovarian carcinoma cell lines, either naturally or via stable gene transfection, tended to confer sensitivity to cisplatin rather than resistance. A statistically significant inverse correlation (r of -0.81) was observed between BCL-2 levels and cisplatin sensitivity in 12 parental ovarian cell lines and transfection of Bcl-2 into A2780 cells conferred a significant increase in sensitivity to cisplatin (and the topoisomerase I inhibitor camptothecin) when using a 96 h growth inhibition assay; (2) no significant correlations were obtained when comparing in vitro drug sensitivity to levels of BAX, BCL XL or BAK or when comparing levels of all four proteins to the platinum response of 12 ovarian cancer xenografts; (3) introduction of Bax into relatively cisplatin resistant lines or BCL XL into a relatively sensitive line did not confer marked changes in chemosensitivity.
Our in vitro results with BCL2 in ovarian cancer differ to many other in vitro studies, especially using cells of haematopoietic origin. Herein, overexpression has been shown to promote cell survival by inhibiting apoptosis induced by a variety of stimuli including chemotherapeutic agents (reviewed in Reed, 1997) . However, two other independent studies also using human epithelial cells (HeLa) and exposure to either aphidicolin or etoposide have shown an inhibition of apoptosis through overexpression of bcl-2 but no difference in clonogenic cell survival (Yin and Schimke, 1995; Lock and Stribinskiene, 1996) . Hence these data agree more closely with our findings where we observed less apoptosis and low level resistance conferred by overexpression of BCL-2 in A2780 cells at 48 h post-treatment, the opposite at 96 h and no difference in clonogenic cell survival. Interestingly, with respect to ovarian cancer, transfection of bcl-2 into A2780 cells caused low level (2.1-to 3.5-fold) cisplatin resistance but in this study, growth inhibition was assessed (by MTT assay) at only 48 h post-cisplatin treatment (Eliopoulos et al, 1995; Herod et al, 1996) . Results from longer term or colony forming assays were not reported. Clinically, in lymphoma, neuroblastoma and leukaemia the overexpression of BCL-2 is associated with an inferior prognosis (reviewed in Reed, 1997) . However, in breast, non-small-cell lung, renal cell, colon and ovarian carcinoma higher expression of BCL-2 is associated with a better outcome (e.g. Herod et al, 1996) .
There was no consistent pattern of BCL-2 expression across various acquired platinum drug-resistant lines, the most notable change being increased expression in a subline possessing resistance to ZD0473 (AMD473), a sterically hindered platinum drug now in phase I trial (Holford et al, 1998) . However, it is unclear to what extent, if any, the BCL-2 overexpression contributes to the acquired resistant phenotype in this line. We observed a differential induction of BAK following cisplatin exposure in the A2780 vector control versus BCL-2 transfect with marked induction in the presence of BCL-2 overexpression compared to a reduction in levels of this pro-apoptotic protein in the vector control. Thus, upregulation of BAK may contribute to the enhanced sensitivity of the BCL-2-transfected line to cisplatin observed by 4-day growth inhibition assays. Also when using A2780 cells, an up-regulation of BAK (and BAX) was observed following paclitaxel or cisplatin treatment (Jones et al, 1998) .
Overall, our results suggest that, at least in human ovarian carcinoma cell lines, high BCL-2 levels (either naturally occurring or through gene transfection) confers a trend towards sensitivity not resistance to platinum drugs.
